{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-114097","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.214316+00:00","generated_at":"2026-05-30T05:29:41.966871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November","bullets":["Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.","Cash, cash equivalents and short-term investments $17.2M as of Sep 30, 2024 (vs $19.1M Dec 31, 2023); runway into 2026.","NXP800 Phase 1b clinical data update expected November 2024; received FDA Orphan Drug Designation for ARID1a-deficient ovarian cancers.","NXP900 Phase 1a dose escalation: 4 cohorts completed with no DLTs; dose continuing; combo plans in NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-114097","json":"https://secwatch.observer/filing/0001104659-24-114097.json","markdown":"https://secwatch.observer/filing/0001104659-24-114097.md","text":"https://secwatch.observer/filing/0001104659-24-114097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924114097/0001104659-24-114097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924114097/tm2427419d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:29:41.966871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}